Bucillamine in Treatment of Patients With COVID-19
Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19
Sponsor: Revive Therapeutics, Ltd.
Terminated
Met definition of futility according to DSMB
This PHASE3 trial investigates Covid19 and is currently terminated or withdrawn. Revive Therapeutics, Ltd. leads this study, which shows 20 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
20 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Terminated PHASE3
Status: Enrolling By Invitation → Terminated
▶ Show 15 earlier versions
-
Nov 2022 — Jul 2023 [monthly]
Enrolling By Invitation PHASE3
-
May 2022 — Nov 2022 [monthly]
Enrolling By Invitation PHASE3
-
Mar 2022 — May 2022 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Enrolling By Invitation PHASE3
-
Dec 2021 — Feb 2022 [monthly]
Enrolling By Invitation PHASE3
-
Oct 2021 — Dec 2021 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Enrolling By Invitation PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Enrolling By Invitation PHASE3
-
May 2021 — Jun 2021 [monthly]
Enrolling By Invitation PHASE3
-
Mar 2021 — May 2021 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Enrolling By Invitation PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Enrolling By Invitation PHASE3
-
Oct 2020 — Dec 2020 [monthly]
Enrolling By Invitation PHASE3
Status: Not Yet Recruiting → Enrolling By Invitation
-
Sep 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Revive Therapeutics, Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .